Quantcast

Latest Bosentan Stories

2009-09-10 10:03:53

Can these drugs help with a wider array of diseases? Expert to address conference of experts Being sponsored by the American Physiological Society (APS) Recent research to block the effects of endothelin, a powerful substance that constricts blood vessels and stimulates cell growth, has led to successful treatment of pulmonary arterial hypertension and provides hope for treating other chronic diseases. The usefulness of the new drugs to treat congestive heart failure is much less clear, said...

2009-09-01 15:00:00

SOUTH SAN FRANCISCO, Calif., Sept. 1 /PRNewswire/ -- Actelion Pharmaceuticals US, Inc., today announced the first commercial sales of a new 20 microgram per milliliter (mcg/mL) formulation of Ventavis(R), for the treatment of New York Heart Association Class III and IV pulmonary arterial hypertension (PAH). This increased strength formulation delivers the same dose of Ventavis in half the volume, which is expected to reduce inhalation time and further support patient compliance. The 20...

2009-06-09 06:00:00

Data Findings Published in June Issue of Circulation SILVER SPRING, Md. and INDIANAPOLIS, June 9 /PRNewswire-FirstCall/ -- United Therapeutics Corporation (Nasdaq: UTHR) and Eli Lilly and Company (NYSE: LLY) today announced the results of a pivotal 16-week study showing that a once-daily dose of tadalafil was generally well tolerated, improved exercise capacity and improved time to clinical worsening in patients with pulmonary arterial hypertension (PAH)(1). The randomized, double-blind,...

2009-05-18 10:12:00

SILVER SPRING, Md., BOSTON and SOUTH SAN FRANCISCO, Calif., May 18 /PRNewswire/ -- The Pulmonary Hypertension Association (PHA), Tufts Medical Center, and Actelion Pharmaceuticals US, Inc., today announced Dr. Nicholas Hill of Tufts Medical Center as the recipient of the 2009 PHA Award of Excellence in Pulmonary Arterial Hypertension (PAH) Care. The grant, in the amount of $50,000, will be awarded to Tufts Medical Center to support continued excellence in care for patients with PAH. The...

2009-02-23 09:00:00

LIBERTY CORNER, N.J., Feb. 23 /PRNewswire/ -- GeneraMedix, Inc. announced today that it has entered into a definitive agreement to sell its improved formulation of epoprostenol sodium for the intravenous treatment of pulmonary arterial hypertension (PAH) to Actelion LTD., a biopharmaceutical company with its headquarters in Allschwil/Basel, Switzerland. Financial terms of the deal were not disclosed. "This sale speaks directly to our company's ongoing commitment to serving the unique...

2008-10-28 12:00:17

Gilead Sciences, Inc. (Nasdaq:GILD) today announced results of a two-year (104-week), open-label, uncontrolled, extension study (ARIES-E) of Letairis(R) in patients with pulmonary arterial hypertension (PAH) (WHO Group 1). Data from this study were presented today at CHEST 2008, the annual meeting of the American College of Chest Physicians, taking place in Philadelphia, October 25-30. Letairis (ambrisentan 5 mg and 10 mg tablets) is indicated as a once-daily treatment for PAH (WHO Group 1)...

2008-09-23 09:00:15

LAVAL, QUEBEC--(Marketwire - Sept. 23, 2008) - Actelion Pharmaceuticals Canada announced today that data presented at the recent European Cardiology Society meeting, and also published in The Lancet(1) show that, even in mildly symptomatic pulmonary arterial hypertension (PAH) patients (WHO functional class II - WHO FC II), the disease progresses very rapidly, such that patients can worsen to the most severe, WHO functional class III and IV in a short period of time. The randomized,...

2008-08-05 06:00:10

Actelion has announced that Tracleer, a dual endothelin receptor antagonist, has been approved in the European Union for the treatment of patients with mildly symptomatic pulmonary arterial hypertension. Tracleer is claimed to be the first pulmonary arterial hypertension (PAH) treatment ever to be investigated in a clinical study that exclusively enrolled patients with mildly symptomatic pulmonary arterial hypertension. This 185-patient randomized, double-blind, placebo-controlled study...

2008-07-22 09:01:13

WALTHAM, Mass., July 22 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that a therapy that improves exercise capacity by a greater percentage than Actelion's Tracleer at 16 weeks, would earn a 48 percent patient share in the treatment of pulmonary arterial hypertension, according to surveyed pulmonologists. Although other efficacy measures are also important to prescribers, they indicate that...

2008-06-24 02:30:29

SILVER SPRING, Md. and SOUTH SAN FRANCISCO, Calif., June 23 /PRNewswire/ -- The Pulmonary Hypertension Association (PHA) and Actelion Pharmaceuticals US, Inc. today announced Robyn Barst as the recipient of the second annual PHA Award of Excellence in Pulmonary Arterial Hypertension (PAH) Care. The grant, in the amount of $50,000, will be awarded to an institution of Dr. Barst's choice in order to support continued excellence in care for patients with PAH. The award, supported by Actelion,...


Word of the Day
malpais
  • The ragged surface of a lava-flow.
'Malpais' translates from Spanish as 'bad land.'